Literature DB >> 12115630

CpG motifs of bacterial DNA exacerbate colitis of dextran sulfate sodium-treated mice.

Florian Obermeier1, Nadja Dunger, Ludwig Deml, Hans Herfarth, Jürgen Schölmerich, Werner Falk.   

Abstract

Inflammatory bowel disease (IBD) is characterized by a dysregulated intestinal immune response with elevated levels of the Th1 cytokines TNF, IL-12 and IFN-gamma. The luminal flora has been implicated as a major factor contributing to the initiation and perpetuation of chronic intestinal inflammation by as yet unknown mechanisms. Bacterial DNA contains unmethylated cytosine-guanosine dinucleotides (CpG) which strongly activate Th1-mediated immune responses. To test whether these CpG-motifs contribute to intestinal inflammation we treated mice with dextran-sulfate-sodium (DSS)-induced acute or chronic colitis for 5 days with CpG-containing oligodeoxynucleotides (CpG-ODN). Colonic inflammation was assessed by histological scoring. Colonic cytokine RNA was quantified by reverse transcription-PCR and cytokine secretion from mesenterial lymph node cells by ELISA. In chronic colitis, CpG-ODN treatment severely aggravated inflammation by 50%. Colonic expression of IFN-gamma and TNF was elevated (200- and 150-fold, respectively) and IFN-gamma and IL-12 secretion from lymph node cells was increased 5,000- and 8-fold, respectively, compared to GpG-ODN-treated controls. Similar effects were obtained in acute colitis. In conclusion, CpG-motifs of bacterial DNA have proinflammatory activity by strengthening the Th1 arm of immunity in DSS-induced colitis, and might therefore play a significant role in the initiation and perpetuation of inflammation in IBD.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12115630     DOI: 10.1002/1521-4141(200207)32:7<2084::AID-IMMU2084>3.0.CO;2-Q

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  38 in total

1.  Intestinal alkaline phosphatase has beneficial effects in mouse models of chronic colitis.

Authors:  Sundaram Ramasamy; Deanna D Nguyen; Michelle A Eston; Sayeda Nasrin Alam; Angela K Moss; Farzad Ebrahimi; Brishti Biswas; Golam Mostafa; Kathryn T Chen; Kanakaraju Kaliannan; Halim Yammine; Sonoko Narisawa; José Luis Millán; H Shaw Warren; Elizabeth L Hohmann; Emiko Mizoguchi; Hans-Christian Reinecker; Atul K Bhan; Scott B Snapper; Madhu S Malo; Richard A Hodin
Journal:  Inflamm Bowel Dis       Date:  2011-02       Impact factor: 5.325

Review 2.  Microbial Nucleic Acid Sensing in Oral and Systemic Diseases.

Authors:  K E Crump; S E Sahingur
Journal:  J Dent Res       Date:  2015-10-05       Impact factor: 6.116

3.  Illuminating the role of type I IFNs in colitis.

Authors:  Stefan Wirtz; Markus F Neurath
Journal:  J Clin Invest       Date:  2005-03       Impact factor: 14.808

Review 4.  NOD2 regulation of Toll-like receptor responses and the pathogenesis of Crohn's disease.

Authors:  T Watanabe; A Kitani; W Strober
Journal:  Gut       Date:  2005-11       Impact factor: 23.059

Review 5.  Inflammatory bowel disease, past, present and future: lessons from animal models.

Authors:  Atsushi Mizoguchi; Emiko Mizoguchi
Journal:  J Gastroenterol       Date:  2008-02-24       Impact factor: 7.527

Review 6.  Immunopathogenesis of inflammatory bowel disease.

Authors:  David Q Shih; Stephan R Targan
Journal:  World J Gastroenterol       Date:  2008-01-21       Impact factor: 5.742

7.  Toll-like receptors mediated signalings: friends or enemies?

Authors:  Yan Zhang
Journal:  Dig Dis Sci       Date:  2013-10       Impact factor: 3.199

Review 8.  Toll-like receptors in inflammatory bowel disease-stepping into uncharted territory.

Authors:  Avi Levin; Oren Shibolet
Journal:  World J Gastroenterol       Date:  2008-09-07       Impact factor: 5.742

9.  Lysozyme promotes the release of Toll-like receptor-2 stimulants from gram-positive but not gram-negative intestinal bacteria.

Authors:  Clett Erridge
Journal:  Gut Microbes       Date:  2010 Nov-Dec

10.  Ameliorating Active Ulcerative Colitis via an Orally Available Toll-Like Receptor-9 Modifier: A Prospective Open-Label, Multicenter Phase II Trial.

Authors:  Iris Dotan; Etgar Levy-Nissenbaum; Yehuda Chowers; Alexander Fich; Eran Israeli; Tomer Adar; Shimon Shteingart; Hermona Soreq; Eran Goldin
Journal:  Dig Dis Sci       Date:  2016-08-29       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.